Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02688712
Recruitment Status : Recruiting
First Posted : February 23, 2016
Last Update Posted : September 15, 2020
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Providence Health & Services

Brief Summary:

The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possible to predict if patients will respond to treatment, and blood samples to look at the immune system response to study treatment.

About 50 people will take part in this study. The study treatment will be given over an 8 week period and the investigators will continue to collect your health information for up to 5 years, as part of this study


Condition or disease Intervention/treatment Phase
Rectal Adenocarcinoma Drug: LY2157299 Drug: Capecitabine Drug: Fluorouracil Procedure: Tumor specific mesorectal excision Phase 2

Detailed Description:

This is a prospective Phase II study to test the efficacy of LY2157299 in combination with neoadjuvant chemoradiation in patients with rectal adenocarcinoma. This study will test the hypothesis that LY2157299 will improve effector T cell tumor infiltration and activity resulting in improved pathologic response rates. The investigators propose that this improved immune response will result in improved disease-free and overall survival.

The objectives are:

  1. Determine the rate of pathologic complete response in patients with locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation and the investigational agent LY2157299
  2. Correlate immunoscore changes prior to therapy, during therapy, and at surgical resection with pathologic response and MRI parameters
  3. Immune monitoring to evaluate potential biomarkers of treatment success.

Eligible patients will have histologically confirmed rectal adenocarcinoma, AJCC Stage IIA IIIC or AJCC Stage IV appropriate for consideration of primary rectal tumor resection. Patients will undergo a forceps biopsy of the rectal mass as part of the diagnostic workup as well as undergo staging evaluation including an MRI with additional study sequences. Enrolled patients will receive a 14 day course of LY2157299 followed by a repeat biopsy and MRI with study sequences. In this trial the investigators plan to use the maximum tolerated dose of LY2157299 established in human clinical trials, 300mg delivered as 150mg P.O. BID. On day 15 patients will begin chemoradiation with either 5-FU (fluorouracil ) or capecitabine (Xeloda®). On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation.

Patients will undergo 50.4 to 54Gy of radiation in 1.8Gy daily fractions delivered Monday through Friday for a total of 28-30 fractions. The acceptable duration of chemoradiation, including treatment breaks or delays, is up to 8 weeks total. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care with evaluation of pathologic response rate. Patients will be followed for disease-free survival, progression free survival, local recurrence, and overall survival. A three patient safety lead-in will be performed, where a six week safety period following completion of radiation will be completed prior to enrolling subsequent patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma
Study Start Date : June 2016
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LY2157299 + Chemoradiation + Surgery
Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
Drug: LY2157299
Small molecule inhibitor of transforming growth factor-beta signaling pathway
Other Name: Galunisertib

Drug: Capecitabine
Antimetabolite chemotherapy
Other Name: Xeloda

Drug: Fluorouracil
Antimetabolite chemotherapy
Other Name: 5-fluorouracil , 5-FU, Adrucil, Efudex, Fluoroplex

Procedure: Tumor specific mesorectal excision
Tumor specific mesorectal excision




Primary Outcome Measures :
  1. Evaluation of pathologic response [ Time Frame: Patients should be evaluated for response at surgery and every 3 months for 2 years and then every 6 months at year three and four. All patients will be followed for survival until death or 5 years post-treatment (whichever comes first) ]
    Complete response is defined as no viable tumor cells identified.


Secondary Outcome Measures :
  1. Immunoscore (utilizing tumor tissue) [ Time Frame: Screening Visit, Day 15 Visit and Day of Surgery ]
    For the immunoscore, a value of 0 or 1 is assigned to each cell population of interest with 0 corresponding to a poor immune infiltrate and 1 corresponding to a favorable immune infiltrate as determined by immunohistochemistry.

  2. MRI Parameters [ Time Frame: Screening Visit and Day 15 Visit ]
    Investigators will test a minimum of three MRI parameters including but not limited to ADC and f_p from the IVIM sequence, and Ktrans from the DCE sequence.

  3. Immunologic monitoring parameters [ Time Frame: Days 1, 15, 22, 29, 43, 57 Visits, and Day of Surgery. ]
    The immunologic monitoring parameters will be combined to arrive at an aggregated measure of "pro-tumor immune environment" or "anti-tumor immune environment" using cell counts derived from flow cytometry of peripheral blood and serum measures of inflammation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients (male and female) with histologically confirmed rectal adenocarcinoma, AJCC Stage IIA-IIIC or AJCC Stage IV appropriate for consideration of primary rectal tumor resection.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Age 18 years or above.
  • Laboratory values (performed within 28 days prior to enrollment) as follows:

    • WBC ≥3.0 109/L
    • Hgb ≥9g/dl (patients may be transfused to reach this level)
    • Platelets ≥99 109 /L
    • Creatinine ≤1.5X upper limit of laboratory normal
    • AST/ALT ≤5 X upper limit of laboratory normal
    • Total bilirubin ≤1.5X upper limit of laboratory normal
    • BNP ≤ 3 times the baseline value and upper limit of laboratory normal
    • Troponin I ≤ upper limit of laboratory normal
    • hsCRP ≤ upper limit of laboratory normal
    • Cystatin ≤ upper limit of laboratory normal
    • PT/INR ≤1.5X upper limit of laboratory normal
  • Pre-menopausal women must have a negative pregnancy test on the day treatment starts and must avoid becoming pregnant while on treatment and for 3 months following completion of therapy. Men must avoid fathering a child while on treatment and for 3 months following completion of therapy. This exclusion is required due to the toxicities that chemotherapy, radiation, and LY2157299 may have on the forming fetus, spermatogenesis or the nursing child. Also, because pregnancy may alter immune function it may limit the treatment efficacy. Women of childbearing potential must agree to use a medically approved contraceptive method during the treatment period and for 3 months following the last dose of LY2157299. Contraceptive methods may include an intrauterine device [IUD], birth control pills or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection.
  • No active bleeding.
  • Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.

Exclusion Criteria:

  • Active infection requiring systemic antibiotics.
  • Active autoimmune disease as defined by the autoimmune disease assessment tool (see protocol)
  • Diagnosis of a solid tumor malignancy (excluding non-melanoma skin cancer) within 3 years of enrollment.
  • History of prior pelvic radiation.
  • Aortic aneurysm (see protocol)
  • Abnormal Echocardiogram (see protocol)
  • Immunodeficiency, need for immunosuppressive medications, or need for chronic steroids.
  • Participation in any investigational drug study within 28 days of enrollment.
  • Pregnant or lactating women, as treatment involves risks to the embryo or fetus.
  • Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in protocol.
  • History of cardiac disease, including myocardial infarction within 6 months before study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension, major cardiac abnormalities, a predisposition for developing aneurysms including family history of aneurysms, Marfan syndrome, bicuspid aortic valve, or evidence of damage to the large vessels of the heart.
  • Concomitant use of strong CYP3A4 inhibitors and inducers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02688712


Contacts
Layout table for location contacts
Contact: Larissa Lundgren (503) 215-2614 Larisa.Lundgren@providence.org

Locations
Layout table for location information
United States, Oregon
Providence Cancer Center Recruiting
Portland, Oregon, United States, 97213
Contact: Larissa Lundgren    503-215-2614    Larisa.Lundgren@providence.org   
Sub-Investigator: Walter J. Urba, M.D., Ph.D         
Sub-Investigator: Rachel Sanborn, MD         
Sub-Investigator: Todd Crocenzi, MD         
Sub-Investigator: Bernard Fox, Ph.D         
Sub-Investigator: Michael Gough, Ph.D.         
Sub-Investigator: Stephen Bader, MD         
Sub-Investigator: Alice Wang-Chesebro, MD         
Sub-Investigator: Matthew Solhjem, MD         
Sub-Investigator: Rui Li, MD, PhD         
Sub-Investigator: Rom Leidner, MD         
Sub-Investigator: Marka Crittenden, MD, PhD         
Sub-Investigator: Steven Seung, MD, PhD         
Sub-Investigator: Mark Whiteford, MD         
Sub-Investigator: David Page, MD         
Sub-Investigator: John Godwin, MD         
Sponsors and Collaborators
Providence Health & Services
Eli Lilly and Company
Investigators
Layout table for investigator information
Principal Investigator: Kristina Young, MD, PhD Providence Health & Services
Principal Investigator: Todd Crocenzi, MD Providence Health & Services
Additional Information:
Layout table for additonal information
Responsible Party: Providence Health & Services
ClinicalTrials.gov Identifier: NCT02688712    
Other Study ID Numbers: 15-050A
First Posted: February 23, 2016    Key Record Dates
Last Update Posted: September 15, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Providence Health & Services:
IIA
Xeloda
radiation therapy
LY2157299
tumor resection
capecitabine
5FU
Fluorouracil
IIB
IIC
IV
neoadjuvant
Rectal cancer
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Rectal Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Fluorouracil
Capecitabine
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs